Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.

Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M.

Eur J Cancer. 2020 Mar 25;130:155-167. doi: 10.1016/j.ejca.2020.02.023. [Epub ahead of print]

PMID:
32220780
2.

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.

Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, Giovannetti E, Fiorentino M, Tiseo M, Petronini PG, Ardizzoni A.

Cancers (Basel). 2020 Mar 12;12(3). pii: E666. doi: 10.3390/cancers12030666.

3.

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial.

Gelsomino F, Tiseo M, Boni L, Cavanna L, Camerini A, Chiari R, Verusio C, Tognetto M, Ardizzoni A.

Ann Oncol. 2019 Apr;30 Suppl 2:ii67-ii68. doi: 10.1093/annonc/mdz063.084. No abstract available.

4.

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC.

Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Tiseo M, Ferracin M, Ardizzoni A.

Ann Oncol. 2019 Apr;30 Suppl 2:ii55-ii56. doi: 10.1093/annonc/mdz063.046. No abstract available.

5.

Clinical significance of ROS1 5' deletions detected by FISH and response to crizotinib.

Dall'Olio FG, Lamberti G, Capizzi E, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A.

Ann Oncol. 2019 Apr;30 Suppl 2:ii54-ii55. doi: 10.1093/annonc/mdz063.044. No abstract available.

6.

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.

Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Garcia MA, Isla D, Jassem J, Appel W, Milanowski J, Van Meerbeeck JP, Wolf J, Li A, Acevedo A, Popat S.

Eur J Cancer. 2020 Mar;127:160-172. doi: 10.1016/j.ejca.2019.11.019. Epub 2020 Feb 3.

7.

Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.

Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, Battelli N, Ardizzoni A, Massari F.

Clin Drug Investig. 2020 Mar;40(3):211-226. doi: 10.1007/s40261-020-00888-5. Review.

PMID:
31993991
8.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.

Di Federico A, Filippini DM, Dall'Olio FG, Conci N, Minari R, Tiseo M, Ardizzoni A.

Clin Cancer Res. 2020 Jan 15;26(2):518-519. doi: 10.1158/1078-0432.CCR-19-2441. No abstract available.

PMID:
31941684
9.

A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease in Steroid Therapy.

Massucci M, Di Fabio F, Rojas Llimpe FL, Ardizzoni A.

J Immunother. 2020 Jan 6. doi: 10.1097/CJI.0000000000000308. [Epub ahead of print]

PMID:
31913208
10.

Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.

Gelsomino F, Di Federico A, Filippini DM, Dall'Olio FG, Lamberti G, Sperandi F, Balacchi C, Brocchi S, Ardizzoni A.

Clin Lung Cancer. 2020 Mar;21(2):e45-e48. doi: 10.1016/j.cllc.2019.11.011. Epub 2019 Nov 20. No abstract available.

PMID:
31902695
11.

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.

Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A.

Ther Adv Med Oncol. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540. eCollection 2019.

12.

Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis.

Rizzo A, Mollica V, Ricci AD, Maggio I, Massucci M, Rojas Limpe FL, Fabio FD, Ardizzoni A.

Future Oncol. 2020 Jan;16(2):4409-4418. doi: 10.2217/fon-2019-0429. Epub 2019 Dec 3.

PMID:
31793342
13.

Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.

Di Nunno V, Mollica V, Schiavina R, Nobili E, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F.

Clin Genitourin Cancer. 2019 Aug 20. pii: S1558-7673(19)30256-3. doi: 10.1016/j.clgc.2019.08.007. [Epub ahead of print]

PMID:
31753738
14.

Emerging therapies in malignant pleural mesothelioma.

Cinausero M, Rihawi K, Cortiula F, Follador A, Fasola G, Ardizzoni A.

Crit Rev Oncol Hematol. 2019 Dec;144:102815. doi: 10.1016/j.critrevonc.2019.102815. Epub 2019 Oct 5. Review.

PMID:
31670225
15.

The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.

Gelsomino F, Lamberti G, Parisi C, Casolari L, Melotti B, Sperandi F, Ardizzoni A.

Cancer Treat Rev. 2019 Sep;79:101887. doi: 10.1016/j.ctrv.2019.08.003. Epub 2019 Aug 8. Review.

PMID:
31491661
16.

Clinical significance of ROS1 5' deletions in non-small cell lung cancer.

Capizzi E, Dall'Olio FG, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A.

Lung Cancer. 2019 Sep;135:88-91. doi: 10.1016/j.lungcan.2019.07.017. Epub 2019 Jul 17.

PMID:
31447007
17.

Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.

Pantaleo MA, Tarantino G, Agostinelli C, Urbini M, Nannini M, Saponara M, Castelli C, Stacchiotti S, Fumagalli E, Gatto L, Santini D, De Leo A, Marafioti T, Akarca A, Sabattini E, Pession A, Ardizzoni A, Indio V, Astolfi A.

Oncoimmunology. 2019 Jun 4;8(9):e1617588. doi: 10.1080/2162402X.2019.1617588. eCollection 2019.

18.

Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.

Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F.

Oncologist. 2019 Nov;24(11):e1228-e1231. doi: 10.1634/theoncologist.2019-0250. Epub 2019 Aug 6.

19.

New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes.

Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F.

Clin Genitourin Cancer. 2019 Oct;17(5):e871-e877. doi: 10.1016/j.clgc.2019.07.001. Epub 2019 Jul 8. Review.

PMID:
31378578
20.

Longitudinal Survey of Fungi in the Human Gut: ITS Profiling, Phenotyping, and Colonization.

Raimondi S, Amaretti A, Gozzoli C, Simone M, Righini L, Candeliere F, Brun P, Ardizzoni A, Colombari B, Paulone S, Castagliuolo I, Cavalieri D, Blasi E, Rossi M, Peppoloni S.

Front Microbiol. 2019 Jul 10;10:1575. doi: 10.3389/fmicb.2019.01575. eCollection 2019.

21.

Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.

Livi V, Ardizzoni A, Cancellieri A, Natali F, Ferrari M, Paioli D, De Biase D, Capizzi E, Tallini G, Fiorentino M, Trisolini R.

Clin Respir J. 2019 Sep;13(9):590-597. doi: 10.1111/crj.13063. Epub 2019 Aug 9.

PMID:
31343834
22.

Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect.

Nuvola G, Dall'Olio FG, Melotti B, Sperandi F, Ardizzoni A.

J Thorac Oncol. 2019 Jul;14(7):e145-e146. doi: 10.1016/j.jtho.2019.02.027. No abstract available.

PMID:
31235038
23.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Nov;24(11):e1165-e1171. doi: 10.1634/theoncologist.2018-0737. Epub 2019 Apr 17.

24.

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.

Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG.

Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019.

25.

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST.

Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, Saponara M, Santini D, Ceccarelli C, Fiorentino M, Vincenzi B, Fumagalli E, Casali PG, Grignani G, Pession A, Ardizzoni A, Astolfi A, Pantaleo MA.

Genes Chromosomes Cancer. 2019 Sep;58(9):636-642. doi: 10.1002/gcc.22753. Epub 2019 Apr 16.

26.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.

J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.

27.

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

Rihawi K, Giannarelli D, Galetta D, Delmonte A, Giavarra M, Turci D, Garassino M, Tiseo M, Barbieri F, Panni S, Ardizzoni A.

J Thorac Oncol. 2019 Mar;14(3):e57-e59. doi: 10.1016/j.jtho.2018.11.036. No abstract available.

28.

Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.

Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizzoni A, Tortora G.

Br J Clin Pharmacol. 2019 Jun;85(6):1283-1289. doi: 10.1111/bcp.13895. Epub 2019 Mar 31.

PMID:
30740760
29.

Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins.

Sala A, Ardizzoni A, Ciociola T, Magliani W, Conti S, Blasi E, Cermelli C.

Intervirology. 2018;61(4):166-173. doi: 10.1159/000494354. Epub 2019 Jan 17.

30.

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.

Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M, Buti S, Bordi P, Aversa F, Ardizzoni A, Quaini F, Tiseo M.

Lung Cancer. 2019 Jan;127:153-163. doi: 10.1016/j.lungcan.2018.11.038. Epub 2018 Nov 29.

PMID:
30642544
31.

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.

Capizzi E, Ricci C, Giunchi F, Zagnoni S, Ceccarelli C, Gómez BUÁ, Casolari L, Gelsomino F, Trisolini R, Fiorentino M, Ardizzoni A.

Lung Cancer. 2018 Dec;126:9-14. doi: 10.1016/j.lungcan.2018.10.017. Epub 2018 Oct 17.

PMID:
30527198
32.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F.

Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047.

PMID:
30486741
33.

Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.

Dall'Olio FG, Sperandi F, Rihawi K, Gargiulo M, Melotti B, Brocchi S, Gelsomino F, Ardizzoni A.

J Thorac Oncol. 2018 Dec;13(12):e247-e248. doi: 10.1016/j.jtho.2018.07.013. No abstract available.

34.

In vitro effects of commercial mouthwashes on several virulence traits of Candida albicans, viridans streptococci and Enterococcus faecalis colonizing the oral cavity.

Ardizzoni A, Pericolini E, Paulone S, Orsi CF, Castagnoli A, Oliva I, Strozzi E, Blasi E.

PLoS One. 2018 Nov 15;13(11):e0207262. doi: 10.1371/journal.pone.0207262. eCollection 2018.

35.

Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC.

Gelsomino F, Facchini G, Barbera MA, Lamberti G, Brocchi S, Rossi G, Ardizzoni A.

J Thorac Oncol. 2019 Jan;14(1):141-143. doi: 10.1016/j.jtho.2018.10.151. Epub 2018 Nov 1. No abstract available.

PMID:
30391575
36.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

37.

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.

Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C.

Target Oncol. 2018 Dec;13(6):705-714. doi: 10.1007/s11523-018-0601-2.

PMID:
30324488
38.

MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report.

Rihawi K, Alfieri R, Fiorentino M, Fontana F, Capizzi E, Cavazzoni A, Terracciano M, La Monica S, Ferrarini A, Buson G, Petronini PG, Ardizzoni A.

Transl Oncol. 2019 Jan;12(1):116-121. doi: 10.1016/j.tranon.2018.09.013. Epub 2018 Oct 2.

39.

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy.

Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, D'Uva G, Győrffy B, Ardizzoni A, Yarden Y, Lauriola M.

Cancers (Basel). 2018 Sep 26;10(10). pii: E355. doi: 10.3390/cancers10100355.

40.

Real-time monitoring of Pseudomonas aeruginosa biofilm formation on endotracheal tubes in vitro.

Pericolini E, Colombari B, Ferretti G, Iseppi R, Ardizzoni A, Girardis M, Sala A, Peppoloni S, Blasi E.

BMC Microbiol. 2018 Aug 14;18(1):84. doi: 10.1186/s12866-018-1224-6.

41.

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.

Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Gatto L, Zichi C, Ardizzoni A, Di Maio M, Massari F.

Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 19. Review.

PMID:
30097230
42.

Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.

Comito F, Ambrosini V, Sperandi F, Melotti B, Ardizzoni A.

Anticancer Drugs. 2018 Nov;29(10):1026-1029. doi: 10.1097/CAD.0000000000000689.

PMID:
30095443
43.

Heterotopic auxiliary segment 2-3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases.

Ravaioli M, Fallani G, Cescon M, Prosperi E, De Pace V, Siniscalchi A, Sangiorgi G, Ferracin M, Ardizzoni A, Morelli MC, Garajová I.

Surgery. 2018 Sep;164(3):601-603. doi: 10.1016/j.surg.2018.05.021. Epub 2018 Jul 2. No abstract available.

PMID:
30041968
44.

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.

Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Oct;29(9):911-913. doi: 10.1097/CAD.0000000000000663.

PMID:
29916898
45.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

46.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M.

Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175.

PMID:
29882691
47.

Is the door open to further investigation with antiangiogenesis in SCLC?

Tiseo M, Boni L, Ardizzoni A.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1127-S1128. doi: 10.21037/jtd.2018.03.87. No abstract available.

48.

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma.

Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Aug;29(7):710-715. doi: 10.1097/CAD.0000000000000644.

PMID:
29846249
49.

Immune-mediated cholangitis: is it always nivolumab's fault?

Gelsomino F, Vitale G, Ardizzoni A.

Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5. No abstract available.

PMID:
29623342
50.

Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

Dall'Olio FG, Brocchi S, Massucci M, Sperandi F, Melotti B, Ardizzoni A.

Eur J Cancer. 2018 May;95:127-129. doi: 10.1016/j.ejca.2018.02.020. Epub 2018 Mar 21. No abstract available.

PMID:
29573943

Supplemental Content

Loading ...
Support Center